Shopping Cart
Remove All
Your shopping cart is currently empty
Vilobelimab (Synonyms: IFX-1, IFX1, CaCP-29, CaCP29)
Catalog No. T76958 Copy Product Info
🥰Excellent
Vilobelimab (CaCP-29) is a human-mouse chimeric IgG antibody targeting human complement component 5a, a C5a inhibitor that inhibits neutrophil activation, and can be used for the study of systemic inflammation caused by SARS-CoV-2 infection.
Vilobelimab
Copy Product Info🥰Excellent
Catalog No. T76958
Synonyms IFX-1, IFX1, CaCP-29, CaCP29
Vilobelimab (CaCP-29) is a human-mouse chimeric IgG antibody targeting human complement component 5a, a C5a inhibitor that inhibits neutrophil activation, and can be used for the study of systemic inflammation caused by SARS-CoV-2 infection.
Vilobelimab
Cas No. 2250440-41-4
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $197 | In Stock | In Stock | |
| 5 mg | $516 | In Stock | In Stock | |
| 10 mg | $828 | - | In Stock | |
| 25 mg | $1,230 | - | In Stock | |
| 50 mg | $1,650 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99% (SDS-PAGE); 98.9% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Vilobelimab (CaCP-29) is a human-mouse chimeric IgG antibody targeting human complement component 5a, a C5a inhibitor that inhibits neutrophil activation, and can be used for the study of systemic inflammation caused by SARS-CoV-2 infection. |
| In vitro | Vilobelimab selectively neutralizes C5a in a dose-dependent manner without preventing the formation of membrane-attacking complexes and has not raised significant safety concerns in certain clinical studies in patients with severe sepsis and septic shock. [1] |
| Synonyms | IFX-1, IFX1, CaCP-29, CaCP29 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | Complement C5 |
| Molecular Weight | 145.86 kDa |
| Cas No. | 2250440-41-4 |
| Isotype | Human IgG4 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Vilobelimab | purchase Vilobelimab | Vilobelimab cost | order Vilobelimab | Vilobelimab in vitro | Vilobelimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.